Mitsubishi UFJ Trust & Banking Corp Sells 100,846 Shares of Pfizer Inc. $PFE

Mitsubishi UFJ Trust & Banking Corp lessened its holdings in shares of Pfizer Inc. (NYSE:PFE) by 3.8% during the 3rd quarter, Holdings Channel.com reports. The fund owned 2,583,854 shares of the biopharmaceutical company’s stock after selling 100,846 shares during the period. Mitsubishi UFJ Trust & Banking Corp’s holdings in Pfizer were worth $65,837,000 as of its most recent SEC filing.

Several other large investors also recently added to or reduced their stakes in the business. Curio Wealth LLC raised its holdings in shares of Pfizer by 36,600.0% during the 2nd quarter. Curio Wealth LLC now owns 1,101 shares of the biopharmaceutical company’s stock valued at $27,000 after purchasing an additional 1,098 shares in the last quarter. Harbor Asset Planning Inc. bought a new position in Pfizer during the second quarter valued at about $29,000. Grey Fox Wealth Advisors LLC acquired a new stake in shares of Pfizer in the third quarter worth about $29,000. Howard Hughes Medical Institute bought a new stake in shares of Pfizer during the 2nd quarter worth about $30,000. Finally, Darwin Wealth Management LLC bought a new position in shares of Pfizer in the 2nd quarter valued at approximately $32,000. 68.36% of the stock is owned by institutional investors.

Pfizer Stock Down 1.7%

NYSE PFE opened at $25.65 on Friday. Pfizer Inc. has a twelve month low of $20.92 and a twelve month high of $27.69. The stock has a market cap of $145.82 billion, a PE ratio of 14.91 and a beta of 0.47. The firm has a 50-day simple moving average of $25.40 and a 200 day simple moving average of $25.01. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.97 and a current ratio of 1.28.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.87 EPS for the quarter, beating the consensus estimate of $0.79 by $0.08. Pfizer had a return on equity of 20.17% and a net margin of 15.65%.The firm had revenue of $16.65 billion during the quarter, compared to analysts’ expectations of $16.94 billion. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. On average, research analysts forecast that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, March 6th. Shareholders of record on Friday, January 23rd will be paid a dividend of $0.43 per share. The ex-dividend date is Friday, January 23rd. This represents a $1.72 dividend on an annualized basis and a yield of 6.7%. Pfizer’s payout ratio is currently 100.00%.

Key Stories Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: NICE recommended Pfizer’s PARP inhibitor Talzenna for adults with prostate cancer — a UK endorsement that supports incremental oncology revenue and validates Pfizer’s targeted?therapy strategy. NICE backs Pfizer’s Talzenna for adults with prostate cancer
• Positive Sentiment: Pfizer launched a large Phase 3 lung?cancer trial positioning its regimen against Merck’s Keytruda — a successful outcome would target a high?value oncology market and materially boost long?term growth expectations. Pfizer Takes Aim at Keytruda in New Phase 3 Lung Cancer Study: What Investors Should Know
• Positive Sentiment: Pfizer moved a COPD candidate into a Phase 2/3 trial, strengthening its post?COVID respiratory pipeline and the company’s addressable market in chronic lung disease. Pfizer Advances New COPD Candidate Into Phase 2/3, Adding Depth to Its Post-COVID Pipeline
• Positive Sentiment: Novavax and Pfizer reached a licensing agreement on the Matrix?M adjuvant — this could reshape Pfizer’s vaccine platform strategy by expanding adjuvant options and serviceable vaccine markets. Novavax inks license agreement with Pfizer
• Positive Sentiment: Early?stage pipeline progress: PF?07248144 advanced with a drug–interaction study and PF?08065010 entered Phase 1 — steady, low?visibility pipeline work that reduces binary risk over time. Pfizer Advances PF-07248144 With New Drug–Interaction Study, Signaling Quiet Pipeline Progress
• Neutral Sentiment: Large options flow: traders bought ~446,836 call options (?+114% vs. typical volume) — indicates short?term bullish/speculative positioning but not a direct fundamental signal. (Market data)
• Neutral Sentiment: CEO Albert Bourla publicly criticized RFK Jr.’s vaccine views and warned the U.S. risks falling behind China in health research — a strong management stance on science and policy that can influence regulatory/public perception but is not an immediate earnings driver. Pfizer CEO Calls RFK’s Vaccine Views Anti-Science, Warns US Falling Behind China In Health Research
• Negative Sentiment: Investor concerns persist on pricing and post?COVID revenue sustainability — recent pieces question whether Pfizer’s current valuation reflects secular headwinds and pricing pressure, which helps explain selling pressure despite pipeline news. Is Pfizer (PFE) Pricing Make Sense After Post Covid Slowdown Concerns
• Negative Sentiment: Opinion pieces highlight a debate whether Pfizer is an attractive dividend/value play or a value trap — ongoing skepticism around growth prospects can keep the stock depressed. Is Pfizer an Absurdly Cheap Dividend Stock, or Just a Value Trap?

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on PFE. The Goldman Sachs Group reaffirmed a “neutral” rating and set a $26.00 target price on shares of Pfizer in a research report on Wednesday, November 5th. HSBC reiterated a “buy” rating and issued a $29.00 target price on shares of Pfizer in a research note on Wednesday, December 10th. Bank of America decreased their price target on shares of Pfizer from $29.00 to $28.00 and set a “neutral” rating for the company in a report on Monday, December 15th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Pfizer in a research note on Thursday. Finally, UBS Group started coverage on Pfizer in a research note on Tuesday, January 6th. They set a “neutral” rating and a $25.00 target price for the company. Two analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, twelve have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $27.88.

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.